Altered Levels of Neonatal Inflammatory Markers Associated with Childhood Leukemia

 A new study finds that children with B-cell precursor acute lymphoblastic leukemia (ALL) have an immune profile at birth that differs from matched controls. Although the cause of ALL remains unknown, this finding lends support to the hypothesis that a dysregulated immune function in combination with certain postnatal environmental exposures leads to the development of the disease.

 

A team at the Statens Serum Institut and University Hospital Rigshospitalet in Copenhagen, Denmark published a paper titled “Neonatal Inflammatory Markers Are Associated with Childhood B-cell Precursor Acute Lymphoblastic Leukemia” in Cancer Research that supports this hypothesis.

 

 

The researchers, led by Henrik Hjalgrim M.D., Ph.D., consultant, department of epidemiology research at Statens Serum Institut, used data from Denmark’s Neonatal Screening Biobank and nationwide registers to conduct a population-based case-control study. They measured the concentrations of inflammatory markers, including cytokines and acute inflammatory proteins, on neonatal dried blood spots from 178 childhood ALL patients and 178 matched leukemia-free controls. They chose children born in Denmark from 1995 to 2008, who were diagnosed with B-cell precursor ALL at ages 1–9 years.

        ❖    Medicilon's Inflammatory & Immune Diseases Models

At present, as the pathogenesis of inflammatory and immunological diseases is unclear, there are few effective therapeutic drugs available in clinical practice. In such a context, the appropriate preclinical research techniques and models are required to help companies and researchers further develop and evaluate new drugs. Our Preclinical Pharmacodynamics Department has been deeply involved in this field for years, developing reliable animal-based efficacy evaluation models aimed at different targets and pathways, thus facilitating the clinical transformation of new drugs.

The team found that neonatal concentrations of eight detectable inflammatory markers were statistically significantly different in children later diagnosed with B-cell precursor acute lymphoblastic leukemia (ALL) when compared with controls. The authors said that they choose these particular markers to “provide a broad picture of the neonatal immune response.”

Related Articles:

Mitochondrial Protein Alterations May Underlie Inflammatory Myopathies

Anti-Inflammatory Mechanism Could Enable Induced Stem Cell Therapies for MS

More specifically, children who developed B-cell precursor ALL had significantly lower neonatal concentrations of IL8, soluble IL6 receptor (sIL6R) α, TGFβ1, monocyte chemotactic protein (MCP)-1, and C-reactive protein (CRP) when compared with matched controls. In addition, the children with ALL had higher concentrations of IL6, IL17, and IL18. Concentrations of IL10 were below the detection level for both patients and controls.

 

The first author on the paper, Signe Holst Søegaard, a graduate student in the department of epidemiology, Statens Serum Institut, says that their findings “suggest that children who develop ALL are immunologically disparate already at birth.” This may link to other observations suggesting that children who develop ALL respond differently to infections in early childhood, potentially promoting subsequent genetic events required for transformation to ALL, or speculations that they are unable to eliminate preleukemic cells.”

 

In addition, the authors found that “birth order (IL18 and CRP), gestational age (sIL6Rα, TGFβ1, and CRP), and sex (sIL6Rα, IL8, and CRP), but not maternal age, infections during pregnancy, birth weight nor mode of delivery were significantly associated with the neonatal concentrations of inflammatory markers.” Søegaard adds that “we demonstrated that several previously shown ALL risk factors, namely birth order, gestational age, and sex were associated with the neonatal concentrations of inflammatory markers.”

 

Although these findings raise the possibility of ALL risk factors acting partly through prenatal programming of immune function, the authors point that their study “does not inform about the nature of the associations observed, i.e., whether they are causal or consequential.”

 

However, the role of a child’s baseline immune characteristics in the development of ALL opens up an important area of research that could lead to tools that predict the development of childhood ALL, allowing for both the targeting of predisposed children and the development of treatments through early immune modulation.